TY - JOUR AU - Cantor Cruz, Francy AU - Gomez-Gomez, Olga AU - Mendivelso Duarte, Fredy AU - Ruiz, Pilar Cristina AU - Rincon Sierra, Oswaldo AU - Yama Mosquera, Erika AU - Moscoso Martinez, Ernesto AU - Bohorquez, Luisa Fernanda AU - Gonzalez, Camilo AU - Acevedo, Juan Ramon AU - Espitia Malagon, Ricardo Antonio AU - Pinto Pinzón, Diego AU - Yomayusa Gonzalez, Nancy PY - 2022/03/22 Y2 - 2024/03/29 TI - GLP-1Ra in the treatment of Type 2 Diabetes Mellitus: An overview of systematic reviews JF - Revista Colombiana de Endocrinología, Diabetes & Metabolismo JA - Rev.ACE VL - 9 IS - 2 SE - Reviews DO - 10.53853/encr.9.2.601 UR - https://revistaendocrino.org/index.php/rcedm/article/view/601 SP - AB - <p><strong>Introduction</strong>: Diabetes mellitus is a serious chronic disease with a worldwide prevalence of 8.5% in people over 18 years of age, of which 90% belong to type 2; A pharmacological option for its management is GLP-1Ra, which has an efficacy in reducing glycosylated hemoglobin (HbA1c) of 0.9 to 1.6%.</p><p><strong>Aim</strong>: To synthesize the evidence from systematic reviews on the safety of GLP-1Ra for cardiovascular and renal outcomes compared with standard therapy in adult patients with T2DM and the reported effectiveness. <strong>Methods</strong>: A comprehensive and systematic literature search was performed on Medline and Ovid with complementary search methods. Data selection and extraction was independent and paired. The methodological quality was evaluated with SING. The following were evaluated as intervention: Liraglutide, Lixisenatide, Albiglutide, Semaglutide, Dulaglutide, Exenatide, Taspoglutide and Efpeglenatide compared with placebo or active therapy.</p><p><strong>Results</strong>: Seventeen studies were included, which grouped 47 unique clinical trials. The results show a trend in the protective effect for cardiovascular and renal outcomes, but very few analyses show to be statistically significant when the molecules are analyzed individually, also reporting contradictions in the direction of the effect for some cardiovascular outcomes.</p><p><strong>Conclusions</strong>: The results should be interpreted with caution given the variability and contradiction in the direction of the effect in some cases. We suggest to decide their use in clinical practice according to the baseline characteristics of the patients and the individual safety results of each molecule.</p> ER -